Relay Therapeutics, Inc. RLAY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $204.59M+144% | $84.02M-8.2% | $91.56M-19.6% | $113.94M+21.8% | $93.54M-24.7% | ||
| $1.34M0.0% | $1.34M-40.8% | $2.26M0.0% | $2.26M+6.6% | $2.12M0.0% | ||
| $11.84M-33.5% | $17.79M-25.4% | $23.84M+48.6% | $16.04M-26.9% | $21.95M+26.5% | ||
| $658.46M+13.9% | $578.28M-7.3% | $624.01M-8.3% | $680.39M-8.0% | $739.66M-8.6% | ||
| $1.22M-29.2% | $1.73M-26.8% | $2.36M-31.8% | $3.46M-32.8% | $5.15M-12.9% | ||
| $38.59M-3.5% | $39.99M-3.3% | $41.37M-3.2% | $42.73M-14.8% | $50.14M-3.1% | ||
| $437.48M-7.0% | $470.5M-6.8% | $504.87M-7.0% | $542.83M-12.0% | $616.81M-6.1% | ||
| $699.61M+12.6% | $621.33M-7.3% | $670M-8.1% | $728.84M-8.8% | $799.36M-8.3% | ||
| $847K+82.9% | $463K-57.1% | $1.08M+77.0% | $609K-63.8% | $1.68M-15.5% | ||
| $3.89M+3.3% | $3.77M+3.3% | $3.64M+3.3% | $3.53M-40.6% | $5.93M+3.5% | ||
| $29.75M+16.3% | $25.58M-21.6% | $32.61M+0.2% | $32.53M-12.2% | $37.05M-27.0% | ||
| $27.68M-3.5% | $28.69M-3.3% | $29.69M-3.2% | $30.66M-25.6% | $41.23M-3.6% | ||
| $57.43M+5.8% | $54.27M-12.9% | $62.29M-1.4% | $63.18M-19.3% | $78.28M-16.3% | ||
| —— | —— | —— | —— | —— | ||
| $182K+8.3% | $168K0.0% | $168K0.0% | $168K0.0% | $168K0.0% | ||
| $2.73B+5.8% | $2.58B+0.5% | $2.57B+0.6% | $2.55B+0.6% | $2.54B+0.8% | ||
| -$2.09B-3.6% | -$2.01B-2.8% | -$1.96B-3.9% | -$1.89B-3.9% | -$1.82B-4.4% | ||
| -$172K-123% | $733K+48.7% | $493K+402% | -$163K-529% | $38K+104% | ||
| $642.18M+13.2% | $567.06M-6.7% | $607.71M-8.7% | $665.66M-7.7% | $721.08M-7.3% | ||
| $699.61M+12.6% | $621.33M-7.3% | $670M-8.1% | $728.84M-8.8% | $799.36M-8.3% | ||
| $4.56M-23.6% | $5.97M+59.6% | $3.74M-50.6% | $7.58M+3.1% | $7.35M-30.2% | ||
| $38.59M-3.5% | $39.99M-3.3% | $41.37M-3.2% | $42.73M-14.8% | $50.14M-3.1% | ||
| $437.48M-7.0% | $470.5M-6.8% | $504.87M-7.0% | $542.83M-12.0% | $616.81M-6.1% | ||
| $38.59M-3.5% | $39.99M-3.3% | $41.37M-3.2% | $42.73M-14.8% | $50.14M-3.1% | ||
| $38.59M-3.5% | $39.99M-3.3% | $41.37M-3.2% | $42.73M-14.8% | $50.14M-3.1% | ||
| $20.91M+53.3% | $13.65M-45.7% | $25.13M+8.3% | $23.22M+10.6% | $20.99M-1.2% | ||
| $20.91M+53.3% | $13.65M-45.7% | $25.13M+8.3% | $23.22M+10.6% | $20.99M-1.2% | ||
| $847K+82.9% | $463K-57.1% | $1.08M+77.0% | $609K-63.8% | $1.68M-15.5% | ||
| $31.57M-2.7% | $32.46M-2.6% | $33.33M-2.5% | $34.18M-27.5% | $47.16M-2.8% | ||
| $182K+8.3% | $168K0.0% | $168K0.0% | $168K0.0% | $168K0.0% | ||
| $11.84M-33.5% | $17.79M-25.4% | $23.84M+48.6% | $16.04M-26.9% | $21.95M+26.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Relay Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 22.13 — current assets exceed current liabilities.
- Where does Relay Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.